Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Fulcrum Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 6 | 19 | 9 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 6 | 19 | 9 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 113 | 119 | 100 | 80 | 84 |
Income After Depreciation & Amortization | -111 | -113 | -81 | -72 | -84 |
Non-Operating Income | 13 | 3 | 0 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -97 | -110 | -81 | -71 | -83 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -97 | -110 | -81 | -71 | -83 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -97 | -110 | -81 | -71 | -83 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -108 | -110 | -79 | -69 | -82 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -111 | -113 | -81 | -72 | -84 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.31 | 44.99 | 35.36 | 25.35 | 11.05 |
Diluted EPS Before Non-Recurring Items | -1.59 | -2.44 | -2.29 | -2.79 | -8.13 |
Diluted Net EPS (GAAP) | -1.59 | -2.44 | -2.29 | -2.79 | -8.13 |
Fiscal Year end for Fulcrum Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 80.00 | 0.00 | 0.87 | 0.76 | 0.88 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 80.00 | 0.00 | 0.87 | 0.76 | 0.88 |
SG&A, R&D, and Dept/Amort Expenses | 27.51 | 29.83 | 28.86 | 28.20 | 28.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | 52.49 | -29.83 | -27.99 | -27.44 | -27.29 |
Non-Operating Income | 2.92 | 2.96 | 3.24 | 3.42 | 3.51 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 55.41 | -26.87 | -24.76 | -24.02 | -23.78 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 55.41 | -26.87 | -24.76 | -24.02 | -23.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 55.41 | -26.87 | -24.76 | -24.02 | -23.78 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 63.59 | 61.98 | 61.87 | 61.82 | 61.79 |
Diluted EPS Before Non-Recurring Items | 0.87 | -0.43 | -0.40 | -0.39 | -0.38 |
Diluted Net EPS (GAAP) | 0.87 | -0.43 | -0.41 | -0.39 | -0.38 |